Before this year, there was no pharmacological treatment available for geographic atrophy.

Following the positive results of two Phase III studies, OAKS and DERBY, Syfovre (pegcetacoplan, Apellis Pharmaceuticals) was approved in February by the FDA and is waiting for the green light by the European Medicine Agency (EMA). In August, also Izervay (avacincaptad pegol, Iveric Bio – Astellas) was approved by the FDA for geographic atrophy, based on the positive outcomes of the GATHER1 and GATHER2 Phase III studies.

In this video Paolo Lanzetta, MD interviews Baruch D. Kuppermann, MD, PhD of the University of California, Irvine. Professor Kuppermann speaks about the experience with these pharmacotherapies in the US, giving pearls and suggestions to his European colleagues.